Related references
Note: Only part of the references are listed.Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
Edward Rosfjord et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
Robert J. Motzer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
Mary Jo Fackler et al.
CANCER RESEARCH (2014)
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Gail D. Lewis Phillips et al.
CLINICAL CANCER RESEARCH (2014)
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
Jian Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
Vivek Subbiah et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L. Rhoda Molife et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Metabolomic Profiling identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
Akash K. Kaushik et al.
JOURNAL OF PROTEOME RESEARCH (2014)
A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group
Jacqueline Anne Hall et al.
LANCET ONCOLOGY (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
EVOLUTION Cancer drivers everywhere?
Darren J. Burgess
NATURE REVIEWS GENETICS (2014)
The impact of whole-genome sequencing on the reconstruction of human population history APPLICATIONS OF NEXT-GENERATION SEQUENCING
Krishna R. Veeramah et al.
NATURE REVIEWS GENETICS (2014)
Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma
Brigitte Dreno et al.
ONCOLOGIST (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Proteomics for discovery of candidate colorectal cancer biomarkers
Paula Alvarez-Chaver et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib
Xiaolin Luo et al.
CANCER DISCOVERY (2014)
Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNA
John A. Martignetti et al.
NEOPLASIA (2014)
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte L. Nielsen et al.
BREAST (2013)
Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives
Ana Custodio et al.
CANCER TREATMENT REVIEWS (2013)
Antibody-Drug Conjugates for the Treatment of Cancer
John A. Flygare et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
Clemens Giessen et al.
CLINICAL CANCER RESEARCH (2013)
Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA
Jacqueline Maier et al.
CLINICAL CANCER RESEARCH (2013)
Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
Michael B. Shea et al.
CLINICAL CANCER RESEARCH (2013)
The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2013)
Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer
Roberta Ferraldeschi et al.
CLINICAL CHEMISTRY (2013)
Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non-Small-Cell Lung Cancer
Scott A. Laurie et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
Nobuyuki Katakami et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
EGFR-directed treatments in SCCHN
Everett E. Vokes et al.
LANCET ONCOLOGY (2013)
Adjuvant bevacizumab: positive data from a negative trial
Jose Perez-Garcia et al.
LANCET ONCOLOGY (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken et al.
LANCET ONCOLOGY (2013)
MASS SPECTROMETRY-BASED PROTEOMICS: THE ROAD TO LUNG CANCER BIOMARKER DISCOVERY
Paola Indovina et al.
MASS SPECTROMETRY REVIEWS (2013)
OPINION Translating metastasis-related biomarkers to the clinic-progress and pitfalls
Francois-Clement Bidard et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Implementing personalized cancer genomics in clinical trials
Richard Simon et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Molecular genetic testing and the future of clinical genomics
Sara Huston Katsanis et al.
NATURE REVIEWS GENETICS (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?
Michael J. Morris et al.
SEMINARS IN ONCOLOGY (2013)
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)
Toni K. Choueiri et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Annette O. Walter et al.
CANCER DISCOVERY (2013)
Adjuvant therapy in primary GIST: state-of-the-art
P. Reichardt et al.
ANNALS OF ONCOLOGY (2012)
Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Timothy A. Yap et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
Ken Herrmann et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Joo Ern Ang et al.
CURRENT DRUG TARGETS (2012)
Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour Considerations for Optimal Management
Heikki Joensuu
DRUGS (2012)
Optimizing the Therapeutic Potential of PD-L1 Blockade as a Single Agent and Through Combination Therapy
B. Irving et al.
EUROPEAN JOURNAL OF CANCER (2012)
Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays
Liping Chung et al.
EXPERT REVIEW OF PROTEOMICS (2012)
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
Andrew J. Weickhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cancer Genomics: Technology, Discovery, and Translation
Ben Tran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Quantitative assessment of dynamic PET imaging data in cancer imaging
Mark Muzi et al.
MAGNETIC RESONANCE IMAGING (2012)
Promise and pitfalls of quantitative imaging in oncology clinical trials
Brenda F. Kurland et al.
MAGNETIC RESONANCE IMAGING (2012)
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
Christine M. Lovly et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
Biomarkers characterization of circulating tumour cells in breast cancer patients
Rosa Nadal et al.
BREAST CANCER RESEARCH (2012)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer
Matthew G. Krebs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Jeeyun Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Deep proteome and transcriptome mapping of a human cancer cell line
Nagarjuna Nagaraj et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Diffusion and Diffusion Tensor Imaging in Brain Cancer
Elizabeth R. Gerstner et al.
SEMINARS IN RADIATION ONCOLOGY (2011)
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
E. D. Saad et al.
ANNALS OF ONCOLOGY (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Carol Pena et al.
CLINICAL CANCER RESEARCH (2010)
Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform
Daniel Summerer et al.
GENOMICS (2010)
A window into third-generation sequencing
Eric E. Schadt et al.
HUMAN MOLECULAR GENETICS (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Awakening Immunity
Hans Schreiber et al.
SCIENCE (2010)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy
Jian-Mei Hou et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications
Marwan K. Tayeh et al.
GENETICS IN MEDICINE (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Fundamentals of Quantitative Dynamic Contrast-Enhanced MR Imaging
Michael J. Paldino et al.
MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA (2009)
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar et al.
NATURE (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma.
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Basic Principles and Technologies for Deciphering the Genetic Map of Cancer
Georgios Voidonikolas et al.
WORLD JOURNAL OF SURGERY (2009)
Molecular pathobiology of gastrointestinal stromal sarcomas
Christopher L. Corless et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Microarray technology and applications in the arena of genome-wide association
Struan F. A. Grant et al.
CLINICAL CHEMISTRY (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer
Ji-Youn Han et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
Falm Eskens et al.
BRITISH JOURNAL OF CANCER (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: Hold back, we are not there yet
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions
Markus Rudin
EUROPEAN RADIOLOGY (2007)
Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group
A. Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T
J. Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group
Jean-Yves Blay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
Giampietro Gasparini et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
Daniel F. Hayes et al.
CLINICAL CANCER RESEARCH (2006)
New technologies and directed agents for applications of cancer imaging
Mostafa Atri
JOURNAL OF CLINICAL ONCOLOGY (2006)
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
Chandrajit P. Raut et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies
Paul Workman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A single nucleotide polymorphism based approach for the identification and characterization of gene expression modulation using MassARRAY
C Jurinke et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2005)
Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy
MC Heinrich et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
DB Agus et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
State-of-the art therapy for gastrointestinal stromal tumors
CD Blanke et al.
CANCER INVESTIGATION (2005)
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity
M Debiec-Rychter et al.
JOURNAL OF PATHOLOGY (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target:: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
J Verweij et al.
EUROPEAN JOURNAL OF CANCER (2003)
The role of functional and molecular imaging in cancer drug discovery and development
BM Seddon et al.
BRITISH JOURNAL OF RADIOLOGY (2003)
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development
P Workman
CURRENT PHARMACEUTICAL DESIGN (2003)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
J Topaly et al.
LEUKEMIA (2001)
Share Paper
